Transcription Factor MYB as Therapeutic Target: Current Developments
Karl-Heinz Klempnauer
Abstract:The MYB protein is a pivotal player in the cellular transcriptional network, influencing major important processes such as cell proliferation, differentiation, and apoptosis. Because of its role in oncogenesis, MYB is now a compelling target for therapeutic interventions in cancer research. This review summarizes its molecular functions and current therapeutic approaches aiming to inhibit its oncogenic activity.
“…The combination of the alkaloid berberine with oligomeric proanthocyanidines revealed synergistic antiproliferative and pro-apoptotic effects in RKO and HT-29 CRC cells based on MYB and AKT downregulation, thus indicating an important role of MYB in the eminent chemoresistance-associated PI3K-AKT signaling pathway [ 225 ] . Natural MYB-p300 inhibitors, either by direct interaction with the MYB-p300 complex or by indirect mechanisms, were summarized recently, and naphthoquinones (naphthazarin, plumbagin, and shikonin), sesquiterpenes (helenalin acetate, mexicanin, and warburganal), the triterpene celastrol, and the steroid lactone withaferin A exhibited notable effects [ 226 , 227 ] . In particular, the MYB-p300 inhibitor celastrol directly blocked the MYB-KIX (kinase-inducible domain interacting domain) interaction of the MYB-p300 complex and showed antiproliferative activity against AML cells along with prolonged survival in an AML mouse model [ 228 ] .…”
Section: Myb Proteins and Cancer Drug Resistancementioning
Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.
“…The combination of the alkaloid berberine with oligomeric proanthocyanidines revealed synergistic antiproliferative and pro-apoptotic effects in RKO and HT-29 CRC cells based on MYB and AKT downregulation, thus indicating an important role of MYB in the eminent chemoresistance-associated PI3K-AKT signaling pathway [ 225 ] . Natural MYB-p300 inhibitors, either by direct interaction with the MYB-p300 complex or by indirect mechanisms, were summarized recently, and naphthoquinones (naphthazarin, plumbagin, and shikonin), sesquiterpenes (helenalin acetate, mexicanin, and warburganal), the triterpene celastrol, and the steroid lactone withaferin A exhibited notable effects [ 226 , 227 ] . In particular, the MYB-p300 inhibitor celastrol directly blocked the MYB-KIX (kinase-inducible domain interacting domain) interaction of the MYB-p300 complex and showed antiproliferative activity against AML cells along with prolonged survival in an AML mouse model [ 228 ] .…”
Section: Myb Proteins and Cancer Drug Resistancementioning
Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.